{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T02:24:01Z","timestamp":1791944641101,"version":"4.3.4"},"reference-count":10,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.annder.2024.103269","type":"journal-article","created":{"date-parts":[[2024,4,27]],"date-time":"2024-04-27T17:33:08Z","timestamp":1714239188000},"page":"103269","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Pruriginous vesicular eruption associated with nivolumab immunotherapy: A case of dermatitis herpetiformis"],"prefix":"10.1016","volume":"151","author":[{"given":"M.","family":"Housset","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Fayad Kazour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Paugam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Le Corre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Croue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Lechevalier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Berthin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.annder.2024.103269_b0005","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.4103\/jcrt.JCRT_1290_16","article-title":"Checkpoint immunotherapy by nivolumab for treatment of metastatic melanoma","volume":"14","author":"Koppolu","year":"2018","journal-title":"J Cancer Res Ther"},{"key":"10.1016\/j.annder.2024.103269_b0010","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1111\/bjd.21781","article-title":"Clinical associations and classification of immune checkpoint inhibitor-induced cutaneous toxicities: a multicentre study from the European academy of dermatology and venereology task force of dermatology for cancer patients","volume":"187","author":"Nikolaou","year":"2022","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.annder.2024.103269_b0015","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1111\/cup.12735","article-title":"Cutaneous autoimmune effects in the setting of therapeutic immune checkpoint inhibition for metastatic melanoma: Cutaneous autoimmune effects of checkpoint inhibitors","volume":"43","author":"Mochel","year":"2016","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.annder.2024.103269_b0020","article-title":"Bullous pemphigoid associated with pembrolizumab therapy for non-small-cell lung cancer: a case report","volume":"14","author":"Chatterjee","year":"2022","journal-title":"Cureus"},{"key":"10.1016\/j.annder.2024.103269_b0025","first-page":"1290","volume":"10","author":"Antiga","year":"2019","journal-title":"Dermatitis Herpetiformis: Novel Perspectives Front Immunol"},{"key":"10.1016\/j.annder.2024.103269_b0030","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1001\/jamadermatol.2018.1912","article-title":"Timing of onset of adverse cutaneous reactions associated with programmed cell death protein 1 inhibitor therapy","volume":"154","author":"Wang","year":"2018","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.annder.2024.103269_b0035","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.annonc.2021.03.204","article-title":"Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma","volume":"32","author":"Owen","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annder.2024.103269_b0040","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.jaad.2020.03.132","article-title":"Immune checkpoint inhibitor-related dermatologic adverse events","volume":"83","author":"Geisler","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2024.103269_b0045","unstructured":"Daniel M. Peraza, Dermatite herp\u00e9tiforme. Dermatite herp\u00e9tiforme, https:\/\/www.msdmanuals.com\/fr\/professional\/troubles-dermatologiques\/maladies-bulleuses\/dermatite-herp%C3%A9tiforme# (2022)."},{"key":"10.1016\/j.annder.2024.103269_b0050","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/COC.0000000000000239","article-title":"CTLA-4 and PD-1 pathways: Similarities, differences, and implications of their inhibition","volume":"39","author":"Buchbinder","year":"2016","journal-title":"Am J Clin Oncol"}],"container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963824000255?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963824000255?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,27]],"date-time":"2024-04-27T21:52:41Z","timestamp":1714254761000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0151963824000255"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":10,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S0151963824000255"],"URL":"https:\/\/doi.org\/10.1016\/j.annder.2024.103269","relation":{},"ISSN":["0151-9638"],"issn-type":[{"value":"0151-9638","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pruriginous vesicular eruption associated with nivolumab immunotherapy: A case of dermatitis herpetiformis","name":"articletitle","label":"Article Title"},{"value":"Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annder.2024.103269","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103269"}}